Skip to main content

Awakn Life Sciences Corp(AWKNF)
OTC US

Today's Change
Delayed Last Update
Volume
Day Low0.1750
Day High0.1823
Open:0.1750
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

Reports for Awakn Life Sciences Corp

News for Awakn Life Sciences Corp

Select a category then submit the form to load news
Newsfile
Awakn Life Sciences Provides Corporate Update
Newsfile
Awakn Life Sciences Submits Clinical Trial Application for Phase III Trial of AWKN-P001
Newsfile
Awakn Life Sciences Completes Sale of Awakn Clinics In Norway
Newsfile
Awakn Life Sciences Completes Sale of Awakn Clinics London
Newsfile
Awakn Life Sciences Announces Results of Annual General and Special Meeting
Newsfile
Awakn Life Sciences to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC
Newsfile
Awakn Life Sciences Announces Closing of the Second Tranche and Upsizing of Previously Announced Private Placement
Newsfile
Awakn Life Sciences to Focus Solely on Research and Development of Therapeutics Targeting Addiction
Newsfile
Awakn Life Sciences Reports Q4 2023 and Annual Results
Newsfile
Awakn Life Sciences Announces Private Placement
Newsfile
Awakn Life Sciences Signs Collaboration Agreement with University of Exeter for Upcoming Phase III Trial
Newsfile
Awakn Life Sciences Increases Ownership of Awakn Bristol to 100% and Provides Corporate Update
Newsfile
Awakn Life Sciences Signs Its Fourth Licensing Partnership Agreement in North America, and First in California
Newsfile
Awakn Life Sciences Announces the Opening of Its Fourth Clinic
Newsfile
Awakn Life Sciences Initiates Feasibility Study for MDMA Using Catalent's Zydis Orally Disintegrating Tablet (ODT) Technology
Newsfile
Awakn Life Sciences Responds to OTC Markets Request on Recent Promotional Activity
Newsfile
Awakn Life Sciences Granted Fast-Track Designation from UK Regulator for Ketamine-Assisted Therapy for Alcohol Use Disorder
Newsfile
Awakn Life Sciences Initiates Investigative Study of Novel Formulation of (S)-ketamine to Assess Dissociative Effect
Baystreet
Inflation Still on Radar Screens in U.S.
Investor Brand Network
BioMedNewsBreaks – Mind Cure Health Inc.’s (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) iSTRYM Opening New Revenue Source, Helping Fuel Further Growth, Expansion
Investor Brand Network
Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Growth Strategy Moves Forward with Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) Partnership for Ketamine-Assisted Psychotherapy Distribution
Investor Brand Network
PsychedelicNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Enters Strategic LOI to Distribute Ketamine Protocol
PR Newswire
MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE's Digital Therapeutics Platform
More Awakn Life Sciences Corp news

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2023.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2023 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.